ONCE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ONCE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Spark Therapeutics's enterprise value is $4,375.09 Mil. Spark Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 was $-240.69 Mil. Therefore, Spark Therapeutics's EV-to-EBITDA for today is -18.18.
The historical rank and industry rank for Spark Therapeutics's EV-to-EBITDA or its related term are showing as below:
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-26), Spark Therapeutics's stock price is $113.57. Spark Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-6.560. Therefore, Spark Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Spark Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spark Therapeutics Annual Data | |||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | - | -20.47 | -10.23 | -5.84 | -5.74 |
Spark Therapeutics Quarterly Data | ||||||||||||||||||||
Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -7.88 | -5.74 | -20.86 | -16.37 | -14.47 |
For the Biotechnology subindustry, Spark Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Spark Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Spark Therapeutics's EV-to-EBITDA falls into.
Spark Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 4375.090 | / | -240.694 | |
= | -18.18 |
Spark Therapeutics's current Enterprise Value is $4,375.09 Mil.
Spark Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-240.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spark Therapeutics (NAS:ONCE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Spark Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 113.57 | / | -6.560 | |
= | At Loss |
Spark Therapeutics's share price for today is $113.57.
Spark Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.560.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Spark Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Elliot Sigal | director | |
Steven Altschuler | director | MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026 |
Stephen W Webster | officer: CHIEF FINANCIAL OFFICER | C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302 |
Daniel Faga | officer: Chief Business Officer | 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104 |
Lota S. Zoth | director, officer: CHIEF SCIENTIFIC OFFICER | 334 CR 692, BUFFALO GAP TX 79508 |
Lars Ekman | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Robert J Perez | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451 |
Anand Mehra | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Vincent Milano | director | C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341 |
Roche Holding Ltd | 10 percent owner | ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070 |
Katherine A High | director, officer: See Remarks | 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104 |
John Furey | officer: Chief Operating Officer | 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104 |
Vivaldi Coelho Rogerio | officer: Chief Commercial Officer | 225 SECOND AVENUE, WALTHAM MA 02451 |
Srinivas Akkaraju | 10 percent owner | 565 EVERETT AVENUE, PALO ALTO CA 94301 |
Sofinnova Venture Partners Viii, L.p. | 10 percent owner | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
From GuruFocus
By Marketwired Marketwired • 01-02-2019
By Marketwired Marketwired • 01-31-2019
By Marketwired Marketwired • 05-08-2018
By Marketwired Marketwired • 08-27-2019
By Marketwired Marketwired • 02-19-2019
By Marketwired Marketwired • 07-31-2018
By Marketwired Marketwired • 04-15-2019
By Marketwired Marketwired • 10-30-2018
By Marketwired Marketwired • 12-03-2018
By PRNewswire PRNewswire • 03-12-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.